Diagnostic Investigation of Sudden Cardiac Event Risk

Completed

Conditions studied: Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD

In brief

The overall objective of the DISCERN study is to develop and validate a genomic diagnostic assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden cardiac death (SCD).

Key facts

Study ID

NCT00500708

Run by

CardioDx

People needed

1564

Starts

2007-07-01

Expected to finish

2011-08-01

Last updated by the study team

2017-10-19

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Implantable cardiac defibrilIator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) implanted for primary prevention
• Left ventricular ejection fraction (LVEF) ≤ 50 %
• Ability to collect clinical follow-up and endpoint information, including device interrogation data

You may not qualify if…

• Congenital heart disease
• Known inherited arrhythmia disorder
• Organ transplantation
• Inability to give informed consent

Where it is running

• Alaska Heart Institute — Anchorage, Alaska, United States
• Palo Alto Medical Foundation — Palo Alto, California, United States
• Minneapolis Heart Institute and Foundation — Minneapolis, Minnesota, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• West Penn Allegheny Health System — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Intermountain Healthcare — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.